This study highlights the potential of YTHDF2 as a therapeutic target and predictor of DLBCL (Chen et al., 2023b).Some studies have shown that m6A shows different heterogeneity in most tumors. This evidence concerns the gene YTHDF2 and diffuse large B-cell lymphoma.